(18)F-fluorodeoxyglucose (FDG) PET or (18)F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

PURPOSE: This study evaluated the ability of (18)F-Fluorodeoxyglucose (FDG) and (18)F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just prior to surgical resection in estrogen receptor positive (ER+) breast tumo...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Romine, Perrin E., Peterson, Lanell M., Kurland, Brenda F., Byrd, Darrin W., Novakova-Jiresova, Alena, Muzi, Mark, Specht, Jennifer M., Doot, Robert K., Link, Jeanne M., Krohn, Kenneth A., Kinahan, Paul E., Mankoff, David A., Linden, Hannah M.
Materialtyp: Online Artikel Text
Språk:English
Publicerad: BioMed Central 2021
Ämnen:
Research Article
Länkar:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381552/
https://www.ncbi.nlm.nih.gov/pubmed/34425871
http://dx.doi.org/10.1186/s13058-021-01464-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381552/
https://www.ncbi.nlm.nih.gov/pubmed/34425871
http://dx.doi.org/10.1186/s13058-021-01464-1

Liknande verk